BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024
BiomX Inc. (NYSE American: PHGE), a clinical-stage company focused on natural and engineered phage therapies, has scheduled a conference call and webcast for November 14, 2024, at 8:00 a.m. ET. The event will cover the company's third quarter 2024 financial results, business updates, and program developments. Participants can join via phone at 1-877-407-0724 (U.S) or 1-201-389-0898 (International). The webcast will be accessible through the Investors section of BiomX's website.
BiomX Inc. (NYSE American: PHGE), un'azienda in fase clinica che si concentra sulle terapie con fagi naturali e ingegnerizzati, ha programmato una conferenza telefonica e un webcast per 14 novembre 2024, alle 8:00 a.m. ET. L'evento tratterà i risultati finanziari del terzo trimestre 2024, aggiornamenti aziendali e sviluppi dei programmi. I partecipanti possono unirsi tramite telefono al numero 1-877-407-0724 (USA) o 1-201-389-0898 (Internazionale). Il webcast sarà accessibile attraverso la sezione Investitori del sito web di BiomX.
BiomX Inc. (NYSE American: PHGE), una empresa en etapa clínica enfocada en terapias con fagos naturales e ingenierizados, ha programado una conferencia telefónica y un webcast para 14 de noviembre de 2024, a las 8:00 a.m. ET. El evento cubrirá los resultados financieros del tercer trimestre de 2024, actualizaciones comerciales y desarrollos de programas. Los participantes pueden unirse por teléfono al 1-877-407-0724 (EE.UU.) o al 1-201-389-0898 (Internacional). El webcast estará accesible a través de la sección de Inversores en el sitio web de BiomX.
BiomX Inc. (NYSE American: PHGE)는 자연 및 엔지니어링 파지 치료를 전문으로 하는 임상 단계 기업으로, 2024년 11월 14일 오전 8:00 ET에 전화 회의 및 웹캐스트를 예정하고 있습니다. 이 행사에서는 2024년 3분기 재무 결과, 사업 업데이트 및 프로그램 개발에 대해 다룰 예정입니다. 참가자는 1-877-407-0724 (미국) 또는 1-201-389-0898 (국제)로 전화에 접속할 수 있습니다. 웹캐스트는 BiomX 웹사이트의 투자자 섹션을 통해 접근 가능합니다.
BiomX Inc. (NYSE American: PHGE), une entreprise en phase clinique spécialisée dans les thérapies par phages naturels et conçus, a programmé une conférence téléphonique et un webcast pour le 14 novembre 2024, à 8h00 ET. L'événement couvrira les résultats financiers du troisième trimestre 2024, les mises à jour de l'entreprise et les développements des programmes. Les participants peuvent se joindre par téléphone au 1-877-407-0724 (États-Unis) ou au 1-201-389-0898 (International). Le webcast sera accessible via la section Investisseurs du site web de BiomX.
BiomX Inc. (NYSE American: PHGE), ein klinisch tätiges Unternehmen, das sich auf natürliche und entwickelte Phagentherapien konzentriert, hat eine Telefonkonferenz und einen Webcast für 14. November 2024, um 8:00 Uhr ET angesetzt. Bei der Veranstaltung werden die Finanzergebnisse des dritten Quartals 2024, Geschäftsupdates und Programmentwicklungen behandelt. Die Teilnehmer können sich telefonisch unter 1-877-407-0724 (USA) oder 1-201-389-0898 (international) einwählen. Der Webcast wird über den Bereich Investoren auf der Website von BiomX zugänglich sein.
- None.
- None.
NESS ZIONA, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, November 14, 2024, at 8:00 a.m. ET, to report third quarter 2024 financial results and provide business and program updates.
To participate in the conference call, please dial 1-877-407-0724 (U.S) or 1-201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company’s website at www.biomx.com.
About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.
BiomX, Inc.
Ben Cohen
benc@biomx.com
FAQ
When will BiomX (PHGE) report Q3 2024 earnings?
How can I access BiomX's (PHGE) Q3 2024 earnings call?
What will BiomX (PHGE) discuss in their November 14 conference call?
